Royalty Financing Serves as Lifeline for Some Biopharma Companies in Uncertain Market

As traditional fundraising methods falter for smaller firms, the rise of royalty deals is reshaping how companies access capital, offering an alternative that bypasses equity dilution and debt.

Scroll to Top